Zevra (ZVRA) stock price, chart and financials

Price chart

Revenue (trailing twelve months)

$136.1M

Revenue (quarter)

$39.7M

Revenue growth (year over year)

+53.25%

Gross profit (trailing twelve months)

$132.5M

Gross margin

97.37%

Net income (trailing twelve months)

$58.3M

Net income (quarter)

$8.8M

Net income growth (year over year)

−88.28%

Net margin

42.82%

Return on equity

34.80%

EPS (trailing twelve months)

$0.96

Book value per share

$3.67

P/E (trailing twelve months)

11.29

Price to book

3.02

Debt to assets

28.10%

Payout ratio

—

Dividend yield

—

Company profile

Zevra Therapeutics Inc is a commercial-stage company with a late-stage pipeline committed to bringing life-changing therapeutics to people living with rare diseases. The Company is focused on expanding patient access, progressing its pipeline toward key milestones, and delivering meaningful outcomes for patients with unmet needs. The commercialization of its product, marketed in the United States for Niemann-Pick disease type C (NPC), a rare, progressive neurodegenerative disease, provides a corporate foundation and demonstrates its ability to advance therapies from development to market.

• Is Zevra (ZVRA) profitable?

  Yes. Zevra earned $58.3M in net income over the trailing twelve months, a net margin of 42.82%.

• How much revenue does Zevra (ZVRA) make?

  Zevra generated $136.1M in revenue over the trailing twelve months, up 53.25% year over year.

• What is ZVRA's P/E ratio?

  Zevra trades at 11.3 times trailing twelve-month earnings, on an EPS of $0.96.

• How do I buy stock in Zevra (ZVRA)?

  ZVRA trades commission-free with a Light Horse Securities brokerage account — from the mobile app, the web dashboard at portal.lighthorse.io, the trading API, or an AI agent connected over MCP. The trade panel on this page places the order once you are signed in.